The US Court of Appeals for the Federal Circuit yesterday, August 6, affirmed a US International Trade Commission decision to uphold a patent related to E. coli bacteria.
Hooper, Lundy and Bookman has appointed Andrew Woodmansee to head up a new IP practice at the firm.
A subsidiary of Irish pharmaceutical company Allergan is to pay a combined total of $2.7 million to three organisations that were part of an antitrust class against the drugmaker.
The European Union has asked the World Trade Organization to establish a panel on Turkey’s measures on pharmaceutical products.
Tensions appear to be running high in the dispute between the Broad Institute of MIT and Harvard and the University of California, Berkeley (UC Berkeley) over which first invented the CRISPR gene-editing technology.
Canadian pharmaceutical company Bausch Health and generics maker Teva have resolved their dispute over Apriso (mesalazine), a drug used to treat ulcerative colitis and Crohn's disease.
In a bid to lower drug prices for American patients, the Trump administration has proposed plans to allow the importation of cheaper drugs from Canada and other countries.
Exact Sciences will acquire Genomic Health in a merger deal worth $2.8 billion.
Biopharmaceutical company Alkermes has entered into a settlement and licence agreement with generic maker Amneal Pharmaceuticals to resolve an inter partes review.
In a defeat for biotech company Celgene, the US Court of Appeals for the Federal Circuit has concluded that the retroactive application of inter partes review proceedings to a pre-American Invents Act patent isn’t unconstitutional.